SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-022350
Filing Date
2022-08-12
Accepted
2022-08-12 16:06:26
Documents
88
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1524973
2 ex31-1.htm EX-31.1 18287
3 ex31-2.htm EX-31.2 18534
4 ex32-1.htm EX-32.1 7556
5 ex32-2.htm EX-32.2 7136
  Complete submission text file 0001493152-22-022350.txt   8157469

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE prph-20220630.xsd EX-101.SCH 60729
7 XBRL CALCULATION FILE prph-20220630_cal.xml EX-101.CAL 100941
8 XBRL DEFINITION FILE prph-20220630_def.xml EX-101.DEF 240550
9 XBRL LABEL FILE prph-20220630_lab.xml EX-101.LAB 519813
10 XBRL PRESENTATION FILE prph-20220630_pre.xml EX-101.PRE 392997
82 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1384166
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-21617 | Film No.: 221160077
SIC: 2834 Pharmaceutical Preparations